SCHEMBL6841323

SCHEMBL6841323

O=[N+]([O-])c1cc(S(=O)(=O)NC(c2ccccc2)c2ccccc2)ccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 10/20 0.61
SLC25A1 P53007 1/20 0.56
DNMT1 P26358 1/20 0.53
DNMT3A Q9Y6K1 1/20 0.53
DOT1L Q8TEK3 1/20 0.51
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ACLY P53396 1/20 0.47
HSPD1 P10809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864492 0.80 VCAM1 (0.70) VCAM1HTTLMNANPBWR1MCHR1
SCHEMBL3619380 0.79 SLC25A1 (0.67) VCAM1SLC25A1DNMT1DNMT3AMEN1
SCHEMBL7262808 0.79 ACLY (0.50) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL6923978 0.77 CA2 (0.59) MEN1KMT2AHTTMAPTLMNA
SCHEMBL6925536 0.76 CA1 (0.59) DOT1LMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4001670 0.75 VCAM1 (0.64) VCAM1SLC25A1MEN1KMT2ANPBWR1
SCHEMBL686821 0.75 VCAM1 (1.00) VCAM1SLC25A1DNMT1DNMT3AMAPT
SCHEMBL2831796 0.75 VCAM1 (0.71) VCAM1SLC25A1DNMT1DNMT3AHTT
SCHEMBL28496538 0.74 VCAM1 (0.74) VCAM1SLC25A1DNMT1DNMT3AHTT
SCHEMBL17085966 0.74 VCAM1 (0.77) VCAM1SLC25A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use WU YONG-QIAN (US) 2004-08-12 US disclosed
US-6656971-B2 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions GUILFORD PHARMACEUTICALS INC. 2003-12-02 US disclosed
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS INC. 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 VCAM1 1050/4885SLC25A1 1605/4885DNMT1 4425/4885
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 VCAM1 1050/4885SLC25A1 1605/4885DNMT1 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.